Shares of Organogenesis Holdings (NASDAQ: ORGO) were down more than 19% as of 11 a.m. on Thursday after the company announced second-quarter earnings and withdrew annual guidance after the markets closed on Wednesday. Organogenesis is a healthcare company that makes advanced care products for the wound-healing process. The company operates in two segments, Advanced Wound Care and Surgical & Sports Medicine, and both saw declines.
ORGO earnings call for the period ending June 30, 2023.
Shares of Organogenesis (NASDAQ: ORGO) were up 15.4% Wednesday afternoon after being up as much as 21.2% Wednesday morning. The healthcare company sells advanced wound care products for surgical and sports medicine applications. Integra LifeSciences said on Tuesday that it was doing a voluntary recall of products, which could be worth as much as $60 million if the recall lasts all of 2023.